Suscribirse

Hypogonadism in adult males with adrenoleukodystrophy - 06/12/25

Doi : 10.1016/j.ando.2025.102464 
Jonanlis Ramirez Alcantara a, b, e, , Natalie R. Grant c, Takara Stanley b, e, Alyssa Halper b, e, f, Florian S. Eichler c, e, Nicholas A. Tritos d, e
a Department of Pediatric Endocrinology, Nicklaus Children's Hospital, Miami, FL, United States 
b Department of Pediatric Endocrinology, Massachusetts General Hospital, Boston, MA, United States 
c Department of Neurology, Massachusetts General Hospital, Boston, MA, United States 
d Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA, United States 
e Harvard Medical School, Boston, MA, United States 
f Takeda Pharmaceuticals, Cambridge, MA, United States 

Corresponding author.

Highlights

.

Teaching points:

Central hypogonadism may occur in males with adrenoleukodystrophy; possible contributing factors may include higher glucocorticoid replacement dose, obesity and the effects of chronic illness;
Compensated primary hypogonadism may also occur in males with adrenoleukodystrophy, likely reflecting testicular dysfunction as a result of VLCFA accumulation in testicular tissues;
Erectile dysfunction is prevalent in males with adrenoleukodystrophy in relation to hypogonadism and/or neurologic dysfunction.

Clinical relevance:

All males with adrenoleukodystrophy should undergo evaluation for hypogonadism and erectile dysfunction as part of their comprehensive care. Use of appropriate glucocorticoid and testosterone replacements as well as phosphodiesterase 5 inhibitor therapies are all integral to optimal patient care in this population;

El texto completo de este artículo está disponible en PDF.

Abstract

Introduction

Hypogonadism has been reported in patients with X-linked adrenoleukodystrophy (ALD), but little is known about prevalence and characteristics. We aimed to further characterize hypogonadism in males with ALD.

Methods

We conducted a retrospective chart review and a prospective study of male children and adults with ALD followed in a multidisciplinary clinic at a tertiary academic center. Serum gonadotropin and testosterone levels defined presence of hypogonadism in adults. Data on symptoms were collected in a survey.

Results

We included 94 males: 56 adults, 32 adolescents and 6 infants. Seven of the 56 adults studied retrospectively (13%) had central hypogonadism. Five of the 49 adults with normal testosterone studied retrospectively (10%), and 7 of the 11 adults studied prospectively (64%) had elevated serum luteinizing hormone and normal testosterone levels, indicative of subclinical compensated primary testicular dysfunction. Adolescents and infants showed no evidence of testicular dysfunction, with normal anti-Müllerian hormone and inhibin levels. Erectile dysfunction was present in 25 of adults with ALD and normal serum testosterone levels (51%), likely reflecting neurologic dysfunction.

Conclusions

Adult males with ALD are at risk of developing central hypogonadism and compensated primary hypogonadism. Adolescents and infants had normal testicular function, suggesting that testicular dysfunction ensues later in life as the disease progresses. Larger prospective studies of ALD cohorts are needed to fully characterize the prevalence and natural history of pituitary-gonadal dysfunction in this population.

El texto completo de este artículo está disponible en PDF.

Keywords : Adrenal insufficiency, Adrenoleukodystrophy, Adrenomyeloneuropathy, Erectile dysfunction, Hypogonadism

Abbreviations : ALD, AMH, AMN, AI, BMI, cALD, FSH, HCG, LC/MS-MS, LH, MRI, SHBG, TT, VLCFA


Esquema


© 2025  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 86 - N° 5

Artículo 102464- septembre 2025 Regresar al número
Artículo precedente Artículo precedente
  • Assessment of diagnostic cutoff for anti-glutamic acid decarboxylase autoantibodies (GADA) measured by a commercial radiobinding assay
  • Romain Vankemmel, Aurore Declomesnil, Madleen Lemaitre, Anne Vambergue, Pascal Pigny
| Artículo siguiente Artículo siguiente
  • Prognostic factors and survival in gastroenteropancreatic neuroendocrine neoplasm: Real-world evidence from a South American Single-Center Cohort
  • Luisana Molina-Pimienta, Andrés A. Cuéllar Cuéllar, Mireya Tapiero-García, Alfredo Romero-Rojas, Jesús O. Sanchez-Castillo

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.